Search research articles
Contact Us
Filters
Showing results (371-380 of 692) with videos related to
Page
of 70
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2010
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer
Astrid A M van der Veldt, N Harry Hendrikse, Hendrik J Harms, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group
G Giaccone, E F Smit, M de Jonge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2003
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
C J Hoekstra, S G Stroobants, O S Hoekstra, et al.
International Journal of Pediatric Otorhinolaryngology
|
May 10, 2017
High prevalence of abnormalities on CT and MR imaging in children with unilateral sensorineural hearing loss irrespective of age or degree of hearing loss
E A van Beeck Calkoen, E Sanchez Aliaga, P Merkus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 7, 2011
Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patients
Barbara S van der Meij, Erik C J Phernambucq, Geert M Fieten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer
Massimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
BMC Cancer
|
March 15, 2023
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Hanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N Storm, et al.
Clinical Radiology
|
January 28, 2010
Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern
A A M van der Veldt, E F I Comans, F B J M Thunnissen, et al.
Molecular Imaging and Biology
|
February 28, 2016
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
Floris H P van Velden, Gerbrand M Kramer, Virginie Frings, et al.
International Journal of Technology Assessment in Health Care
|
October 24, 2002
Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach
Paul Verboom, G Judith M Herder, Otto S Hoekstra, et al.
Page
of 70
Search research articles
Search
Showing results (371-380 of 692) with videos related to
Sort By:
Page
of 70
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2010
Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer
Astrid A M van der Veldt, N Harry Hendrikse, Hendrik J Harms, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group
G Giaccone, E F Smit, M de Jonge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 13, 2003
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
C J Hoekstra, S G Stroobants, O S Hoekstra, et al.
International Journal of Pediatric Otorhinolaryngology
|
May 10, 2017
High prevalence of abnormalities on CT and MR imaging in children with unilateral sensorineural hearing loss irrespective of age or degree of hearing loss
E A van Beeck Calkoen, E Sanchez Aliaga, P Merkus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 7, 2011
Nutrition during trimodality treatment in stage III non-small cell lung cancer: not only important for underweight patients
Barbara S van der Meij, Erik C J Phernambucq, Geert M Fieten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2009
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer
Massimo Di Maio, Paolo Chiodini, Vassilis Georgoulias, et al.
BMC Cancer
|
March 15, 2023
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Hanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N Storm, et al.
Clinical Radiology
|
January 28, 2010
Re: Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern
A A M van der Veldt, E F I Comans, F B J M Thunnissen, et al.
Molecular Imaging and Biology
|
February 28, 2016
Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
Floris H P van Velden, Gerbrand M Kramer, Virginie Frings, et al.
International Journal of Technology Assessment in Health Care
|
October 24, 2002
Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach
Paul Verboom, G Judith M Herder, Otto S Hoekstra, et al.
Page
of 70